*Division of Immunobiology, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Department of Medical Biochemistry, Max F. Perutz Laboratories, Vienna Biocenter, and Institute of Vascular Biology, Medical University of Vienna, Austria; Laboratory for Transcriptional Regulation, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan; and CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
*Division of Immunobiology, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Department of Medical Biochemistry, Max F. Perutz Laboratories, Vienna Biocenter, and Institute of Vascular Biology, Medical University of Vienna, Austria; Laboratory for Transcriptional Regulation, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan; and CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
J Leukoc Biol. 2015 Apr;97(4):635-44. doi: 10.1189/jlb.1HI1113-597RR. Epub 2014 Dec 29.
CD8 coreceptor expression is dynamically regulated during thymocyte development and is tightly controlled by the activity of at least 5 different cis-regulatory elements. Despite the detailed characterization of the Cd8 loci, the regulation of the complex expression pattern of CD8 cannot be fully explained by the activity of the known Cd8 enhancers. In this study, we revisited the Cd8ab gene complex with bioinformatics and transgenic reporter gene expression approaches to search for additional Cd8 cis-regulatory elements. This led to the identification of an ECR (ECR-4), which in transgenic reporter gene expression assays, directed expression preferentially in CD44(hi)CD62L(+) CD8(+) T cells, including innate-like CD8(+) T cells. ECR-4, designated as Cd8 enhancer E8VI, was bound by Runx/CBFβ complexes and Bcl11b, indicating that E8VI is part of the cis-regulatory network that recruits transcription factors to the Cd8ab gene complex in CD8(+) T cells. Transgenic reporter expression was maintained in LCMV-specific CD8(+) T cells upon infection, although short-term, in vitro activation led to a down-regulation of E8VI activity. Finally, E8VI directed transgene expression also in CD8αα(+) DCs but not in CD8αα-expressing IELs. Taken together, we have identified a novel Cd8 enhancer that directs expression in CD44(hi)CD62L(+) CD8(+) T cells, including innate-like and antigen-specific effector/memory CD8(+) T cells and in CD8αα(+) DCs, and thus, our data provide further insight into the cis-regulatory networks that control CD8 expression.
CD8 核心受体的表达在胸腺细胞发育过程中是动态调节的,受至少 5 个不同顺式调控元件的活性的严格控制。尽管 Cd8 基因座的特征已被详细描述,但 Cd8 基因的复杂表达模式的调控不能仅通过已知的 Cd8 增强子的活性来完全解释。在这项研究中,我们使用生物信息学和转基因报告基因表达方法重新研究了 Cd8ab 基因复合物,以寻找额外的 Cd8 顺式调控元件。这导致了 ECR(ECR-4)的鉴定,该 ECR 在转基因报告基因表达实验中,优先指导 CD44(hi)CD62L(+)CD8(+)T 细胞的表达,包括先天样 CD8(+)T 细胞。ECR-4 被 Runx/CBFβ 复合物和 Bcl11b 结合,表明 E8VI 是招募转录因子到 CD8(+)T 细胞中 Cd8ab 基因复合物的顺式调控网络的一部分。在 LCMV 特异性 CD8(+)T 细胞感染后,转基因报告基因表达得以维持,尽管短期体外激活导致 E8VI 活性下调。最后,E8VI 也指导 CD8αα(+)DCs 中的转基因表达,但不指导 CD8αα 表达的 IELs 中的表达。总之,我们已经鉴定了一个新的 Cd8 增强子,该增强子在 CD44(hi)CD62L(+)CD8(+)T 细胞中指导表达,包括先天样和抗原特异性效应/记忆 CD8(+)T 细胞和 CD8αα(+)DCs,因此,我们的数据为控制 CD8 表达的顺式调控网络提供了进一步的见解。